Primary Clinical Response of Relmacabtagene Autoleucel in Adults with Relapsed/Refractory Follicular Lymphoma (r/r FL) in China

被引：0
|
作者：
Song, Yuqin [1 ]
Ying, Zhitao [1 ]
Yang, Haiyan [2 ]
Guo, Ye [3 ]
Li, Wenyu [4 ]
Zou, Dehui [5 ,6 ,7 ]
Wu, Jianqiu [8 ]
Yang, Su [9 ]
Zhang, Pian [9 ]
Ma, Meilin [9 ]
Zhou, Zisong [9 ]
Zheng, Hongxia [9 ]
Zhu, Jun [1 ]
机构：
[1] Peking Univ Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China
[2] Chinese Acad Sci, Inst Canc & Basic Med IBMC, Dept Med Oncol, Hangzhou, Peoples R China
[3] Shanghai Dongfang Hosp, Tongji Univ, Dept Med Oncol, Shanghai, Peoples R China
[4] Guangdong Acad Sci, Dept Lymphoma, Guangdong Provincial Peoples Hosp, Guangzhou, Guangdong, Peoples R China
[5] Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Blood Dis Hosp, Tianjin, Peoples R China
[6] Chinese Acad Med Sci, Inst Hematol, Tianjin, Peoples R China
[7] Peking Union Med Coll, Tianjin, Peoples R China
[8] Affiliated Hosp Nanjing Med Univ, Jiangsu Inst Canc Res, Jiangsu Canc Hosp, Dept Med Oncol,Jiangsu Red Cross Canc Ctr, Nanjing, Peoples R China
[9] JW Therapeut Shanghai Co Ltd, Shanghai, Peoples R China
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-150085
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2434
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Long-term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) With Relapsed/Refractory (r/r) Follicular Lymphoma (FL) Treated With Tisagenlecleucel in the ELARA Trial
    Dreyling, M.
    Dickinson, M.
    Martinez-Lopez, J.
    Kolstad, A.
    Butler, J.
    Ghosh, M.
    Popplewell, L.
    Chavez, J. C.
    Bachy, E.
    Kato, K.
    Harigae, H.
    Kersten, M. J.
    Andreadis, C.
    Riedell, P. A.
    Ho, P. J.
    Perez-Simon, J. A.
    Chen, A. I.
    Nastoupil, L. J.
    Tresckow, B. V.
    Ferreri, Maria A. J.
    Teshima, T.
    Patten, P. E.
    McGuirk, J. P.
    Petzer, A.
    Offner, F.
    Viardot, A.
    Zinzani, P. L.
    Malladi, R.
    Paule, I.
    Zia, A.
    Awasthi, R.
    Han, X.
    Germano, D.
    O'Donovan, D.
    Ramos, R.
    Masood, A.
    Thieblemont, C.
    Fowler, N.
    Schuster, S. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 306 - 308
  • [22] Clinical Outcomes of Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated With Tisagenlecleucel: Phase 2 ELARA 3-Year Follow-Up
    Schuster, Stephen J.
    Fowler, Nathan Hale
    Dickinson, Michael
    Martinez-Lopez, Joaquin
    Kolstad, Arne
    Butler, Jason
    Ghosh, Monalisa
    Popplewell, Leslie
    Chavez, Julio C.
    Bachy, Emmanuel
    Kato, Koji
    Harigae, Hideo
    Kersten, Marie Jose
    Andreadis, Charalambos
    Riedell, Peter A.
    Ho, P. Joy
    Perez-Simon, Jose Antonio
    Chen, Andy I.
    Nastoupil, Loretta J.
    von Tresckow, Bastian
    Ferreri, Andres Jose Maria
    Teshima, Takanori
    Patten, Piers E. M.
    McGuirk, Joseph P.
    Petzer, Andreas L.
    Offner, Fritz
    Viardot, Andreas
    Zinzani, Pier Luigi
    Malladi, Ram
    Zia, Aiesha
    Awasthi, Rakesh
    Paule, Ines
    Germano, Davide
    Ramos, Roberto
    Hsu, Pei
    Thieblemont, Catherine
    Dreyling, Martin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S495 - S496
  • [23] Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial
    Dreyling, Martin
    Dickinson, Michael
    Martinez Lopez, Joaquin
    Kolstad, Arne
    Butler, Jason P.
    Ghosh, Monalisa
    Popplewell, Leslie L.
    Chavez, Julio
    Bachy, Emmanuel
    Kato, Koji
    Harigae, Hideo
    Kersten, Marie Jose
    Andreadis, Charalambos
    Riedell, Peter A.
    Ho, Phoebe Joy
    Perez-Simon, Jose A.
    Chen, Andy
    Nastoupil, Loretta J.
    von Tresckow, Bastian
    Ferreri, Andres J. M.
    Teshima, Takanori
    Patten, Piers E. M.
    McGuirk, Joseph P.
    Petzer, Andreas
    Offner, Fritz
    Viardot, Andreas
    Zinzani, Pier Luigi
    Malladi, Ram
    Paule, Ines
    Zia, Aiesha
    Awasthi, Rakesh
    Han, Xia
    Germano, Davide
    O'Donovan, Darragh
    Ramos, Roberto
    Masood, Aisha
    Thieblemont, Catherine
    Fowler, Nathan H.
    Schuster, Stephen J.
    BLOOD, 2022, 140 : 1459 - 1463
  • [24] Results of the PI3Kδ inhibitor ME-401 alone or with rituximab in relapsed/refractory (R/R) follicular lymphoma (FL).
    Zelenetz, Andrew David
    Jagadeesh, Deepa
    Reddy, Nishitha M.
    Stathis, Anastasios
    Salman, Huda S.
    Asch, Adam Steven
    Kenkre, Vaishalee Padgaonkar
    Jhangiani, Haresh S.
    Iasonos, Alexia
    Soumerai, Jacob D.
    Llorin, Judith
    Pagel, John M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] Long-term follow-up of patients (pts) with relapsed or refractory (r/r) follicular lymphoma (FL) treated with copanlisib.
    Leppa, Sirpa
    Santoro, Armando
    Demeter, Judit
    Follows, George
    Lenz, Georg
    Kim, Won Seog
    Mollica, Luigina
    Nagler, Arnon
    Diong, Colin Phipps
    Provencio, Mariano
    Stevens, Don A.
    Trevarthen, David R.
    Wang, MingLu
    Wirtz, Oliver
    Miriyala, Ashok
    Vargas, Jose Garcia
    Childs, Barrett H.
    Zinzani, Pier Luigi
    Dreyling, Martin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] Efficacy and safety of Tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 ELARA trial
    Schuster, S.
    Dickinson, M.
    Dreyling, M.
    Martinez-Lopez, J.
    Kolstad, A.
    Butler, J.
    Ghosh, M.
    Popplewell, L.
    Chavez, J.
    Bachy, E.
    Kato, K.
    Harigae, H.
    Kersten, M. J.
    Andreadis, C.
    Riedell, P.
    Zia, A.
    Morisse, M. C.
    Fowler, N. H.
    Thieblemont, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 104 - 105
  • [27] Long-term follow-up shows epcoritamab drives deep, durable responses in relapsed/refractory follicular lymphoma (R/R FL)
    Izutsu, K.
    Akahane, D.
    Toubai, T.
    Saito, T.
    Mishima, Y.
    Fujisaki, T.
    Kitawaki, T.
    Kumode, T.
    Suehiro, Y.
    Ishitsuka, K.
    Conlon, R.
    Noguchi, H.
    Buchbjerg, J.
    Favaro, E.
    Fukuhara, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S1337 - S1337
  • [28] Randomized Phase 2 Zanubrutinib (BGB-3111) + Obinutuzumab Vs Obinutuzumab Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL)
    Fowler, Nathan H.
    Trotman, Judith
    Auer, Rebecca
    Flowers, Christopher R.
    Reed, William F.
    Ivanova, Elena
    Huang, Jane
    Zinzani, Pier Luigi
    BLOOD, 2019, 134
  • [29] A Budget-Impact (BI) Analysis of Tazemetostat for the Treatment of 3L+Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States
    Watson, Lucy
    Harrison, Owen
    Cockrum, Paul
    Veazey, Kylee
    Gaugris, Sabine
    Kim, George
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S498 - S499
  • [30] Matching-Adjusted Indirect Comparison (MAIC) of efficacy and safety for tisagenlecleucel and mosunetuzumab in patients (pts) with Relapsed/Refractory (r/r) Follicular Lymphoma (FL)
    Dreyling, M.
    Fowler, N.
    Schuster, S.
    Yang, H.
    Xiang, C.
    Ramos, R.
    Maier, H.
    Jousseaume, E.
    Thieblemont, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 50 - 51
12345